Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Addex Therapeutics (ADXN) EBIT Margin (2019 - 2025)

Addex Therapeutics' EBIT Margin history spans 7 years, with the latest figure at 314218.95% for Q4 2025.

  • On a quarterly basis, EBIT Margin fell 13152664.0% to 314218.95% in Q4 2025 year-over-year; TTM through Dec 2025 was 3360.2%, a 210390.0% decrease, with the full-year FY2025 number at 9390.76%, down 870894.0% from a year prior.
  • EBIT Margin came in at 314218.95% for Q4 2025, down from 2342.13% in the prior quarter.
  • The five-year high for EBIT Margin was 62.8% in Q2 2023, with the low at 314218.95% in Q4 2025.
  • Historically, EBIT Margin has averaged 28854.78% across 5 years, with a median of 1086.74% in 2022.
  • Biggest five-year swings in EBIT Margin: surged 1089379bps in 2021 and later plummeted -18123060bps in 2024.
  • Year by year, EBIT Margin stood at 3901.0% in 2021, then rose by 11bps to 3463.7% in 2022, then surged by 58bps to 1461.7% in 2023, then crashed by -12399bps to 182692.31% in 2024, then crashed by -72bps to 314218.95% in 2025.
  • Business Quant data shows EBIT Margin for ADXN at 314218.95% in Q4 2025, 2342.13% in Q3 2025, and 182692.31% in Q4 2024.